Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review

Edina Amponsah-Dacosta, Benjamin M Kagina, Jill Olivier, Edina Amponsah-Dacosta, Benjamin M Kagina, Jill Olivier

Abstract

Given the vast investments made in national immunization programmes (NIPs) and the significance of NIPs to public health, it is important to understand what influences the optimal performance of NIPs. It has been established that well-performing NIPs require enabling health systems. However, systematic evidence on how the performance of health systems impacts on NIPs is lacking, especially from sub-Saharan Africa. We conducted a qualitative systematic review to synthesize the available evidence on health systems constraints and facilitators of NIPs in sub-Saharan Africa, using human papillomavirus immunization programmes as a proxy. Fifty-four articles published between 2008 and 2018 were found to be eligible. Data extraction was guided by an analytical model on the interface between NIPs and health systems. A cross-cutting thematic analysis of the extracted data was performed. This systematic review provides evidence necessary for informing ongoing health systems strengthening initiatives in sub-Saharan Africa. There is evidence to suggest that NIPs in sub-Saharan Africa have surmounted significant health systems constraints and have achieved notable public health success. This success can be attributed to strong political endorsement for vaccines, clear governance structures and effective collaboration with global partners. Despite this, significant health systems constraints persist in service delivery, vaccine communication, community engagement, the capacity of the health workforce and sustainable financing. These constraints could derail further progress if not addressed through health systems strengthening efforts. There is a need to expand the research agenda to include the comprehensive evaluation of health systems constraints and facilitators of NIPs within sub-Saharan Africa.

Keywords: Africa; HPV vaccine; cervical cancer; health systems; human papillomavirus; immunization; national immunization programmes.

© The Author(s) 2020. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.

Figures

Figure 1
Figure 1
Global progress in the implementation of nationwide HPV immunization programmes. Data from countries with planned or partial HPV vaccine introduction, or HPV vaccine demonstration projects, are not represented here [drawing on data from http://www.hpvcentre.net, WHO (2019), Gallagher et al. (2018), LaMontagne et al. (2017) and Herrero et al. (2015)].
Figure 2
Figure 2
An analytical model for in-depth assessment of the interface between NIPs and health systems.
Figure 3
Figure 3
Flowchart of the literature search and selection process. †Reasons for exclusion: study outcomes not relevant for this systematic review (n = 68); study design not relevant for this systematic review (n = 55); wrong study population (n = 13); duplicate records (n = 6); full-text unavailable (n = 4); and wrong study period (pre-2008) (n = 1).
Figure 4
Figure 4
Summary of health systems constraints and facilitators of HPV immunization programmes in sub-Saharan Africa.

References

    1. Ali SF, Ayub S, Manzoor NF. et al. 2010. Knowledge and awareness about cervical cancer and its prevention amongst interns and nursing staff in tertiary care hospitals in Karachi, Pakistan. PLoS One 5: e11059.
    1. Arah OA, Klazinga NS, Delnoij DMJ. et al. 2003. Conceptual frameworks for health systems performance: a quest for effectiveness, quality, and improvement. International Journal for Quality in Health Care 15: 377–98.
    1. Arbyn M, Weiderpass E, Bruni L. et al. 2020. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Global Health 8: e191–e203.
    1. Arevshatian L, Clements CJ, Lwanga SK. et al. 2007. An evaluation of infant immunization in Africa: is a transformation in progress? Bulletin of the World Health Organization 85: 449–57.
    1. Audu BM, Bukar M, Ibrahim AI. et al. 2014. Awareness and perception of human papillomavirus vaccine among healthcare professionals in Nigeria. Journal of Obstetrics and Gynaecology 34: 714–7.
    1. Ayissi C, Wamai R, Oduwo G. et al. 2012. Awareness, acceptability and uptake of human papillomavirus vaccine among Cameroonian school-attending female adolescents. Journal of Community Health 37: 1127–35.
    1. Balabanova D, McKee M, Mills A. et al. 2010. What can global health institutions do to help strengthen health systems in low income countries? Health Research Policy and Systems 8: 22.
    1. Bardají A, Mindu C, Augusto OJ. et al. 2018. Awareness of cervical cancer and willingness to be vaccinated against human papillomavirus in Mozambican adolescent girls. Papillomavirus Research 5: 156–62.
    1. Bello FA, Enabor OO, Adewole IF.. 2011. Human papillomavirus vaccination for control of cervical cancer: a challenge for developing countries. African Journal of Reproductive Health 15: 25–30.
    1. Bonner K, Banura C, Basta NE.. 2018. HPV vaccination strategies targeting hard-to-reach populations: out-of-school girls in LMICs. Vaccine 36: 191–3.
    1. Botha MH, van der Merwe FH, Snyman LC. et al. 2015. The vaccine and cervical cancer screen (VACCS) project: acceptance of human papillomavirus vaccination in a school-based programme in two provinces of South Africa. South African Medical Journal 105: 40–3.
    1. Botwright S, Holroyd T, Nanda S. et al. 2017. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS One 12: e0182663.
    1. Bowser D, Marqusee H, El Koussa M, Atun R.. 2017. Health system barriers and enablers to early access to breast cancer screening, detection, and diagnosis: a global analysis applied to the MENA region. Public Health 152: 58–74.
    1. Bruni L, Diaz M, Barrionuevo-Rosas L. et al. 2016. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Global Health 4: e463.
    1. Cartmell KB, Young-Pierce J, McGue S. et al. 2018. Barriers, facilitators, and potential strategies for increasing HPV vaccination: a statewide assessment to inform action. Papillomavirus Research 5: 21–31.
    1. Chan Z. 2013. A systematic review of critical thinking in nursing education. Nurse Education Today 33: 236–40.
    1. Chawla PC, Chawla A, Chaudhary S.. 2016. Knowledge, attitude & practice on human papillomavirus vaccination: a cross-sectional study among healthcare providers. The Indian Journal of Medical Research 144: 741–9.
    1. Chee G, Pielemeier N, Lion A. et al. 2013. Why differentiating between health system support and health system strengthening is needed. The International Journal of Health Planning and Management 28: 85–94.
    1. Chigbu CO, Onyebuchi AK, Onyeka TC. et al. 2017. The impact of community health educators on uptake of cervical and breast cancer prevention services in Nigeria. International Journal of Gynecology & Obstetrics 137: 319–24.
    1. Coleman MA, Levison J, Sangi-Haghpeykar H.. 2011. HPV vaccine acceptability in Ghana, West Africa. Vaccine 29: 3945–50.
    1. Colvin CJ, Konopka S, Chalker JC. et al. 2014. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-infected pregnant and postpartum women. PLoS One 9: e108150.
    1. De Groot AS, Tounkara K, Rochas M. et al. 2017. Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS One 12: e0171631.
    1. de Martel C, Plummer M, Vignat J. et al. 2017. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer 141: 664–70.
    1. De Vuyst H, Alemany L, Lacey C. et al. 2013. The burden of human papillomavirus infections and related diseases in sub-Saharan Africa. Vaccine 31: F32–46.
    1. Denny LA, Sankaranarayanan R, De Vuyst H. et al. 2012. Recommendations for cervical cancer prevention in sub-Saharan Africa. Vaccine 31: F74.
    1. DiAngi YT, Panozzo CA, Ramogola-Masire D. et al. 2011. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS One 6: e25481.
    1. Francis SA, Battle-Fisher M, Liverpool J. et al. 2011. A qualitative analysis of South African women’s knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine 29: 8760–5.
    1. Francis SA, Nelson J, Liverpool J. et al. 2010. Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine 28: 8026–32.
    1. Friedman AL, Oruko KO, Habel MA. et al. 2014. Preparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Health 14: 855.
    1. Gallagher KE, Howard N, Kabakama S. et al. 2017a. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016. Papillomavirus Research 4: 72–8.
    1. Gallagher KE, Howard N, Kabakama S. et al. 2017b. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries. PLoS One 12: e0177773.
    1. Gallagher KE, LaMontagne DS, Watson-Jones D.. 2018. Status of HPV vaccine introduction and barriers to country uptake. Vaccine 36: 4761–7.
    1. Garcini LM, Galvan T, Barnack-Tavlaris JL.. 2012. The study of human papillomavirus (HPV) vaccine uptake from a parental perspective: a systematic review of observational studies in the United States. Vaccine 30: 4588–95.
    1. Garland SM, Kjaer SK, Muñoz N. et al. 2016. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clinical Infectious Diseases 63: 519–27.
    1. Goeman L, Galichet B, Porignon DG. et al. 2010. The response to flexibility: country intervention choices in the first four rounds of the GAVI health systems strengthening applications. Health Policy and Planning 25: 292–9.
    1. Hanvoravongchai P, Mounier-Jack S, Oliveira Cruz V. et al. 2011. Impact of measles elimination activities on immunization services and health systems: findings from six countries. The Journal of Infectious Diseases 204: S82–9.
    1. Harries J, Moodley J, Barone MA. et al. 2009. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 27: 38–44.
    1. Hendry M, Lewis R, Clements A. et al. 2013. “HPV? Never heard of it!”: a systematic review of girls’ and parents’ information needs, views and preferences about human papillomavirus vaccination. Vaccine 31: 5152–67.
    1. Herrero R, González P, Markowitz LE.. 2015. Present status of human papillomavirus vaccine development and implementation. The Lancet. Oncology 16: e216.
    1. Hopkins TG, Wood N.. 2013. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 31: 1673–9.
    1. Hoque ME. 2015. Acceptability of human papillomavirus vaccination among academics at the University of KwaZulu-Natal, South Africa. South African Family Practice 57: 318–21.
    1. Hoque ME. 2016. Factors influencing the recommendation of the human papillomavirus vaccine by South African doctors working in a tertiary hospital. African Health Sciences 16: 567–75.
    1. Hoque ME, Ghuman S, Hal GV.. 2013. Human papillomavirus vaccination acceptability among female university students in South Africa. Asian Pacific Journal of Cancer Prevention 14: 4865–9.
    1. Hutubessy R, Levin A, Wang S. et al. 2012. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool. BMC Medicine 10: 136.
    1. Kamya C, Shearer J, Asiimwe G. et al. 2017. Evaluating global health partnerships: a case study of a Gavi HPV vaccine application process in Uganda. International Journal of Health Policy and Management 6: 327–38.
    1. Kane GA, Wood VA, Barlow J.. 2007. Parenting programmes: a systematic review and synthesis of qualitative research. Child: Care, Health and Development 33: 784–93.
    1. Katz IT, Nkala B, Dietrich J. et al. 2013. A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS One 8: e72094.
    1. Kessels SJM, Marshall HS, Watson M. et al. 2012. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 30: 3546–56.
    1. Kruk ME, Freedman LP.. 2008. Assessing health system performance in developing countries: a review of the literature. Health Policy 85: 263–76.
    1. Ladner J, Besson M, Hampshire R. et al. 2012. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 12: 370.
    1. Ladner J, Besson M, Rodrigues M. et al. 2014. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health 14: 670.
    1. LaMontagne DS, Barge S, Le NT. et al. 2011. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bulletin of the World Health Organization 89: 821–30B.
    1. LaMontagne DS, Bloem PJN, Brotherton JML. et al. 2017. Progress in HPV vaccination in low‐ and lower‐middle‐income countries. International Journal of Gynecology & Obstetrics 138: 7–14.
    1. Langley JM. 2015. Adolescent immunization—protecting youth and preparing them for a healthy future. International Journal of Pediatrics and Adolescent Medicine 2: 1–6.
    1. Levin CE, Van Minh H, Odaga J. et al. 2013. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Vietnam. Bulletin of the World Health Organization 91: 585–92.
    1. Louie KS, de Sanjose S, Mayaud P.. 2009. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Tropical Medicine & International Health 14: 1287–302.
    1. Lu B, Kumar A, Castellsague X. et al. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infectious Diseases 11: 13.
    1. Mabeya H, Menon S, Weyers S.. et al. 2018. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a maleria endemic setting. BMC Cancer 18:557.
    1. Machingaidze S, Wiysonge CS, Hussey GD.. 2013. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Medicine 10: e1001405.
    1. MacPhail C, Venables E, Rees H. et al. 2013. Using HPV vaccination for promotion of an adolescent package of care: opportunity and perspectives. BMC Public Health 13: 493.
    1. Makwe CC, Anorlu RI.. 2011. Knowledge of and attitude toward human papillomavirus infection and vaccines among female nurses at a tertiary hospital in Nigeria. International Journal of Women’s Health 3: 313–7.
    1. Marchal B, Cavalli A, Kegels G.. 2009. Global health actors claim to support health system strengthening—is this reality or rhetoric? PLoS Medicine 6: e1000059.
    1. Maseko FC, Chirwa ML, Muula AS.. 2015. Cervical cancer control and prevention in Malawi: need for policy improvement. Pan African Medical Journal 22: 247.
    1. Masika MM, Ogembo JG, Chabeda SV. et al. 2015. Knowledge on HPV vaccine and cervical cancer facilitates vaccine acceptability among school teachers in Kitui County, Kenya. PLoS One 10: e0135563.
    1. Massey PM, Boansi RK, Gipson JD. et al. 2017. Human papillomavirus (HPV) awareness and vaccine receptivity among Senegalese adolescents. Tropical Medicine & International Health 22: 113–21.
    1. Mehta B, Chawla S, Kumar V, Jindal H, Bhatt B.. 2014. Adult immunization: the need to address. Human Vaccines & Immunotherapeutics 10: 306–9.
    1. Mihigo R, Okeibunor J, Anya B. et al. 2017. Challenges of immunization in the African Region. Pan African Medical Journal 27: 12.
    1. Moodley I, Tathiah N, Mubaiwa V. et al. 2013. High uptake of Gardasil vaccine among 9–12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. South African Medical Journal 103: 318–21.
    1. Morhason-Bello IO, Wallis S, Adedokun BO. et al. 2015. Willingness of reproductive-aged women in a Nigerian community to accept human papillomavirus vaccination for their children. Journal of Obstetrics and Gynaecology Research 41: 1621–9.
    1. Mounier-Jack S, Burchett HED, Griffiths UK. et al. 2014. Measuring the health systems impact of disease control programmes: a critical reflection on the WHO building blocks framework. BMC Public Health 14: 278.
    1. Msyamboza KP, Mwagomba BM, Valle M. et al. 2017. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges. BMC Public Health 17: 599.
    1. Mugisha E, LaMontagne DS, Katahoire AR. et al. 2015. Feasibility of delivering HPV vaccine to girls aged 10 to 15 years in Uganda. African Health Sciences 15: 33–41.
    1. Murray CJL, Evans D.. 2003. Health systems performance assessment: debates, methods and empiricism. , accessed 12 March 2020.
    1. Murray CJL, Frenk J.. 2000. A framework for assessing the performance of health systems. Bulletin of the World Health Organization 78: 717–31.
    1. Nanni A, Meredith S, Gati S. et al. 2017. Strengthening global vaccine access for adolescents and adults. Vaccine 35: 6823–7.
    1. Ndizeye Z, Vanden Broeck D, Vermandere H. et al. 2018. Knowledge and practices of general practitioners at district hospitals towards cervical cancer prevention in Burundi, 2015: a cross-sectional study. Globalization and Health 14: 4.
    1. Ngabo F, Levin A, Wang SA. et al. 2015. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine 33: 7357–63.
    1. Nganwai P, Truadpon P, Inpa C. et al. 2008. Knowledge, attitudes and practices vis-a-vis cervical cancer among registered nurses at the Faculty of Medicine, Khon Kaen University, Thailand. Asian Pacific Journal of Cancer Prevention 9: 15–8.
    1. Odunyemi FT, Ndikom CM, Oluwatosin OA.. 2018. Effect of nursing intervention on mothers’ knowledge of cervical cancer and acceptance of human papillomavirus vaccination for their adolescent daughters in Abuja—Nigeria. Asia-Pacific Journal of Oncology Nursing 5: 223–30.
    1. Ogembo JG, Manga S, Nulah K. et al. 2014. Achieving high uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming challenges. Vaccine 32: 4399–403.
    1. Okunade KS, Sunmonu O, Osanyin GE. et al. 2017. Knowledge and acceptability of human papillomavirus vaccination among women attending the gynaecological outpatient clinics of a university teaching hospital in Lagos, Nigeria. Journal of Tropical Medicine 2017: 1–6.
    1. Oluwole D, Kraemer J; Pink Ribbon Red Ribbon. 2013. Innovative public-private partnership: a diagonal approach to combating women’s cancers in Africa. Bulletin of the World Health Organization 91: 691–6.
    1. Ouzzani M, Hammady H, Fedorowicz Z. et al. 2016. Rayyan-a web and mobile app for systematic reviews. Systematic Reviews 5: 210.
    1. Poole DN, Tracy JK, Levitz L. et al. 2013. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS One 8: e56402.
    1. Ports KA, Reddy DM, Rameshbabu A.. 2013. Barriers and facilitators to HPV vaccination: perspectives from Malawian women. Women & Health 53: 630–45.
    1. Quentin W, Terris-Prestholt F, Changalucha J. et al. 2012. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Medicine 10: 137.
    1. Remes P, Selestine V, Changalucha J. et al. 2012. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Vaccine 30: 5363–7.
    1. Rosen BL, Shepard A, Kahn JA.. 2018. US health care clinicians’ knowledge, attitudes, and practices regarding human papillomavirus vaccination: a qualitative systematic review. Academic Pediatrics 18: S53–S65.
    1. SAGE. 2016. Midterm review of the global vaccine action plan. , accessed 12 March 2020.
    1. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G. et al. 2012. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine 31: F52.
    1. Shen AK, Fields R, McQuestion M.. 2014. The future of routine immunization in the developing world: challenges and opportunities. Global Health: Science and Practice 2: 381–94.
    1. Tchounga BK, Jaquet A, Coffie PA. et al. 2014. Cervical cancer prevention in reproductive health services: knowledge, attitudes and practices of midwives in Côte d’Ivoire, West Africa. BMC Health Services Research 14: 165.
    1. Torres-Rueda S, Rulisa S, Burchett HED. et al. 2016. HPV vaccine introduction in Rwanda: impacts on the broader health system. Sexual & Reproductive Healthcare 7: 46–51.
    1. Travis P, Bennett S, Haines A. et al. 2004. Overcoming health-systems constraints to achieve the millennium development goals. The Lancet 364: 900–6.
    1. Turiho AK, Okello ES, Muhwezi WW.. et al. 2014. Effect of school-based human papillomavirus (hpv) vaccination on adolescent girls' knowledge and acceptability of the HPV vaccine in Ibanda District in Uganda. African Journal of Reproductive Health 18: 45–53.
    1. Turiho AK, Okello ES, Muhwezi WW. et al. 2017. Perceptions of human papillomavirus vaccination of adolescent schoolgirls in western Uganda and their implications for acceptability of HPV vaccination: a qualitative study. BMC Research Notes 10: 431.
    1. Ugwu EO, Obi SN, Ezechukwu PC. et al. 2013. Acceptability of human papillomavirus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Nigerian Journal of Clinical Practice 16: 249–52.
    1. Umeh IB, Nduka SO, Ekwunife OI.. 2016. Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: a cross sectional contingent valuation study. Cost Effectiveness and Resource Allocation 14: 8.
    1. Urasa M, Darj E.. 2011. Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. African Health Sciences 11: 48–57.
    1. Venturas C, Umeh K.. 2017. Health professional feedback on HPV vaccination roll-out in a developing country. Vaccine 35: 1886–91.
    1. Vermandere H, Naanyu V, Degomme O. et al. 2015. Implementation of an HPV vaccination program in Eldoret, Kenya: results from a qualitative assessment by key stakeholders. BMC Public Health 15: 875.
    1. Vermandere H, Naanyu V, Mabeya H. et al. 2014. Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS One 9: e109353.
    1. Walter FM, Emery J, Braithwaite D. et al. 2004. Lay understanding of familial risk of common chronic diseases: a systematic review and synthesis of qualitative research. The Annals of Family Medicine 2: 583–94.
    1. Wamai RG, Ayissi CA, Oduwo GO. et al. 2013. Awareness, knowledge and beliefs about HPV, cervical cancer and HPV vaccines among nurses in Cameroon: an exploratory study. International Journal of Nursing Studies 50: 1399–406.
    1. Wang SA, Hyde TB, Mounier-Jack S. et al. 2013. New vaccine introductions: assessing the impact and the opportunities for immunization and health systems strengthening. Vaccine 31: B122–8.
    1. Watson-Jones D, Mugo N, Lees S. et al. 2015. Access and attitudes to HPV vaccination amongst hard-to-reach populations in Kenya. PLoS One 10: e0123701.
    1. Watson-Jones D, Tomlin K, Remes P. et al. 2012. Reasons for receiving or not receiving HPV vaccination in primary schoolgirls in Tanzania: a case control study. PLoS One 7: e45231.
    1. Watt N, Sigfrid L, Legido-Quigley H. et al. 2017. Health systems facilitators and barriers to the integration of HIV and chronic disease services: a systematic review. Health Policy and Planning 32: iv13–26.
    1. WHO. 2007. Everybody’s business—strengthening health systems to improve health outcomes: WHO’s framework for action. , accessed 13 March 2020.
    1. WHO. 2011. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. , accessed 13 March 2020.
    1. WHO. 2013a. The expanded programme on immunization. , accessed 13 March 2020.
    1. WHO. 2013b. Global Vaccine Action Plan 2011-2020. accessed 13 March 2020.
    1. WHO. 2015. WHO’s mission and vision in immunization and vaccines 2015-2030. , accessed 13 March 2020.
    1. WHO. 2017a. Human papillomavirus vaccines: WHO position paper, May 2017. Weekly Epidemiological Record 92: 241–68.
    1. WHO. 2017b. Human papillomavirus vaccines: WHO position paper, May 2017—recommendations. Vaccine 35: 5753–5.
    1. WHO. 2019. WHO vaccine-preventable diseases: monitoring system. 2019 Global summary. accessed 13 March 2020.
    1. WHO. 2018. WHO regional office for Africa. , accessed 13 march 2020.
    1. Wigle J, Coast E, Watson-Jones D.. 2013. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects. Vaccine 31: 3811–7.
    1. World Health Organization Maximizing Positive Synergies Collaborative Group, Samb B, Evans T. et al.2009. An assessment of interactions between global health initiatives and country health systems. Lancet (London, England) 373: 2137–69.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel